SU105264A1 - Method of treating coronary insufficiency - Google Patents
Method of treating coronary insufficiencyInfo
- Publication number
- SU105264A1 SU105264A1 SU555690A SU555690A SU105264A1 SU 105264 A1 SU105264 A1 SU 105264A1 SU 555690 A SU555690 A SU 555690A SU 555690 A SU555690 A SU 555690A SU 105264 A1 SU105264 A1 SU 105264A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- coronary insufficiency
- treating coronary
- daukarin
- drug
- insufficiency
- Prior art date
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
Известны способы лечени коронарной недостаточности с помощью ннтро1 тицерина, амил-нитрита. валидола и других лекарственных средств, оказывающих кратковременное действие.Methods are known for treating coronary insufficiency with nitrocytin, amyl nitrite. validol and other drugs that have a short-term effect.
Предлагаетс способ .лечени коронарной недостаточности нрепаратом даукарнн, оказывающим более длите.тьноесосудораспп-1р ющееA method is proposed for treating coronary insufficiency by the preparation Daucarnn, which has a longer duration of the vessel.
дейстр.ие, чем перечисленные лекарства .action than listed drugs.
Препарат даукарин нрсдставл ет из себ суммарный очищенный экстракт из сем н моркови огородной Daycus Sativus (ПоЬт) Rochl (семейство зонтичных) и относнтс к веществам сназмо.читического де11стви . Он обладает способностью расщир ть коронарные сосуды сердца и нримен етс дл лечени коронарной недостаточности.The preparation daukarin is derived from the total purified extract from carrot seeds of the Daycus sativus (Pocht) Rochl (family of umbrella) carrots from the garden plant and relates to the substances of sleep pseudopathy. It has the ability to dilate the coronary vessels of the heart and is used to treat coronary insufficiency.
Даукарин не обрывает уже зозникншй Приступ стенокардии, так как терапевтический эффект наступает через 3-5 дней после начала приема препарата.Daukarin does not interrupt the already active attack of angina, as the therapeutic effect occurs 3-5 days after the start of taking the drug.
Выпускаетс в виде таблеток весомAvailable in pill weight.
0,1 с с содержанием даукарина 0,02 г. Назначаетс внутрь по 1 таб.тетке (по 0,02 г) :-т 3 до 5 р;:; в день за 30 мннут до еды.0.1 s with a daukarin content of 0.02 g. It is administered orally on 1 tablet (0.02 g each): -t 3 to 5 r;:; per day for 30 minutes before meals.
Длнтельпость леченн от двух до четырех недель.Long-term treatment is from two to four weeks.
Протипоказани к применению препарата не установлено.Protypes to the use of the drug is not installed.
Пренарат даукарин разреи е} к применению в медицпнсхо ; практике Фармакологическим комитетом Ученого Совета Министерства здравоохраненн СССР.Prenarate Daukarin resolution e} for use in medicine; the practice of the Pharmacological Committee of the Scientific Council of the Ministry of Health of the USSR.
Предмет и з о б р с т е н и Subject and B about with with and N and
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU555690A SU105264A1 (en) | 1956-08-02 | 1956-08-02 | Method of treating coronary insufficiency |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU555690A SU105264A1 (en) | 1956-08-02 | 1956-08-02 | Method of treating coronary insufficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
SU105264A1 true SU105264A1 (en) | 1956-11-30 |
Family
ID=48378681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU555690A SU105264A1 (en) | 1956-08-02 | 1956-08-02 | Method of treating coronary insufficiency |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU105264A1 (en) |
-
1956
- 1956-08-02 SU SU555690A patent/SU105264A1/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Betz et al. | The relationship of the therapist to the outcome of therapy in schizophrenia. | |
SU105264A1 (en) | Method of treating coronary insufficiency | |
GB1157717A (en) | Method and Apparatus for Processing Garlic | |
MAY et al. | Parkinsonian reactions following chlorpromazine and reserpine: Similar reactions in the same patients | |
Pecknold et al. | Lack of indication for use of antiparkinson medication: A follow-up study. | |
Holdway | Trial of imipramine | |
Dallas | Penicillin treatment failures in male gonorrhoea | |
Keeton et al. | Dramatic respiratory symptoms induced by sudden withdrawal of ACTH | |
RU2582282C1 (en) | Method of producing agent having stress protective and anti-hypoxic activity | |
SU114346A1 (en) | Method of treating gallstone disease in humans | |
FUJIHIRA | On the treatment of eight cases of valvular disease of the heart | |
SU94959A1 (en) | A method of treating hypertension with liver drug "antisimpatin" | |
SU135426A1 (en) | Drug olitorizid | |
Haessler et al. | H. Clinical, bacteriologic and serologic data in leptospiral uveitis. Arch. f. Ophth. | |
FR1056M (en) | Pharmaceutical product intended for the treatment of circulatory disorders of the upper or lower limbs. | |
Chamberlain et al. | Clinical experience with the oral administration of cedilanid, and a comparison of the oral and intravenous preparations of cedilanid with digitalis purpurea | |
SU110654A1 (en) | A method for the treatment of diseases accompanied by spasms of smooth muscle organs | |
SU98807A1 (en) | Method of treating diseases of the central nervous system | |
ZAKON et al. | Introduction of quinacrine in treatment of lupus erythematosus | |
SU148758A1 (en) | The way to standardize heart remedies | |
Kline et al. | EFFECTS OF ANTIBIOTICS ON MUSCLE-NERVE REACTIONS OF FROGS | |
Aaron | IONTOPHORESIS OF PYRIBENZAMINE | |
Lundholm | The growth of the psychological self:(I) Character. | |
Davletkildeeva | Materials on the use of adrenocorticotropic hormone and cortisone in clinics of 6 internal diseases | |
LEWiS | Diuresis and the caffein group of diuretics |